LNSR Stock Performance, Insider Transaction and News

LNSR - LENSAR, Inc.

Market Cap	34.49M	P/E	-	EPS this Y	-16.00%	Ern Qtrly Grth	-
Income	-12.56M	Forward P/E	-4.11	EPS next Y	46.70%	50D Avg Chg	-15.00%
Sales	45.12M	PEG	-	EPS past 5Y	-	200D Avg Chg	-7.00%
Dividend	N/A	Price/Book	0.87	EPS next 5Y	-	52W High Chg	-54.00%
Recommedations	1.50	Quick Ratio	2.00	Shares Outstanding	11.61M	52W Low Chg	62.00%
Insider Own	19.58%	ROA	-10.15%	Shares Float	8.50M	Beta	0.64
Inst Own	41.97%	ROE	-29.95%	Shares Shorted/Prior	69.74K/59.60K	Price	3.08
Gross Margin	49.87%	Profit Margin	-27.83%	Avg. Volume	41,353	Target Price	8.00
Oper. Margin	-12.27%	Earnings Date	Nov 7	Volume	4,305	Change	-3.75%

Healthcare | Medical Devices | United States

About LENSAR, Inc.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LENSAR, Inc. News

11/09/24	LENSAR Third Quarter 2024 Earnings: Beats Expectations
11/08/24	LENSAR Inc (LNSR) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion
11/07/24	LENSAR Reports Third Quarter 2024 Results and Provides Business Update
11/01/24	LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/31/24	LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
10/30/24	LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
10/09/24	Lensar announces more than 1M procedures completed with cataract laser systems
10/08/24	One Millionth Procedure Completed Using LENSAR’s Cataract Laser Systems
09/04/24	LENSAR to Participate in Two Upcoming Investor Conferences
08/10/24	LENSAR Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24	LENSAR Reports Second Quarter 2024 Results and Provides Business Update
08/07/24	LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union
08/01/24	LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
05/23/24	LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
05/13/24	LENSAR, Inc. (NASDAQ:LNSR) Q1 2024 Earnings Call Transcript
05/12/24	LENSAR, Inc. (NASDAQ:LNSR) Just Reported, And Analysts Assigned A US$8.00 Price Target
05/11/24	LENSAR First Quarter 2024 Earnings: EPS Beats Expectations
05/09/24	LENSAR Reports First Quarter 2024 Results and Provides Business Update
05/02/24	LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
04/17/24	We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth

LNSR Chatroom

RallyRaider Posted - 2 days ago

$LNSR super breakout

PenkeTrading Posted - 2 weeks ago

I found you an Overbought RSI (Relative Strength Index) on the daily chart of LENSAR Inc. Is that bullish or bearish? $LNSR #LENSAR #RsiOverbought #NASDAQ

HaisleyBarry Posted - 2 weeks ago

MYNZ moving +12.25% in PM and opening climbing up same with volume 🚀 All is buying, ready for the squeeze. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. $AZTA $LNSR $SGMA $BE

Doozio Posted - 10/28/24

$LNSR da FUTUre of 🧠⏰ is NOW during 🧠⏰♾️

RallyRaider Posted - 1 month ago

$LNSR suuuuper thin this onw knows how to move

RallyRaider Posted - 1 month ago

$LNSR #$$$$$$

SmartContent Posted - 1 month ago

$OSS The defense sector has reliable, long-term demand, and their contracts with the U.S. Special Operations Command for rugged AI solutions place them in a stable, high-growth area. Government contracts provide a strong revenue base, and AI has increasing applicability across sectors. $MODD FDA clearance for the MODD1 insulin pump is a significant milestone, and the personalized metabolic therapy space is growing. Early movers in FDA-approved medical devices can see strong returns as they penetrate the market. $GNSS global contracts for emergency response systems offer consistent growth and strong demand in niche markets. Their contract security and international reach make them a good balance of growth and stability. $LNSR leads in ophthalmic devices, especially with over a million cataract procedures.

SmartContent Posted - 1 month ago

<$5 worth a look: STTK Insider buying signals confidence, SL-325 autoimmune therapy. UGRO Secured 12M in new cannabis contracts, positioning for strong growth with potential Florida market expansion. MODD FDA clearance of the MODD1 insulin pump sets the stage for growth in personalized metabolic therapy. ASRV Maintains dividends and focuses on regional growth. OSS Strengthened its defense sector presence with a contract from US S.O. Command for rugged AI solutions. $PHX is benefiting from record royalty volumes and a significant dividend increase. $GNSS continues to expand globally, securing critical contracts for its advanced emergency response systems. $DALN is driving innovation with a new voter engagement tool for the 2024 election, enhancing digital reach. $LNSR leads in ophthalmic devices, having surpassed one million cataract procedures with its cutting-edge laser systems. $LFMD is expanding telehealth offerings, especially in weight management, with rising demand for GLP-1 therapies.

Playthegame06 Posted - 1 month ago

$LNSR 1,000,000th procedure completed using Lensar Lasar Systems.

Chiroptera_Capital Posted - 2 months ago

$ICAD $LNSR both of these will be acquired. It’s just a question of when and for how much.